• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

净效益和胜率统计推断方法的评估。

Evaluation of inferential methods for the net benefit and win ratio statistics.

机构信息

DSI, I-Biostat, University Hasselt , Hasselt, Belgium.

Neurobiology Research Unit, Rigshospitalet and University of Copenhagen , Copenhagen, Denmark.

出版信息

J Biopharm Stat. 2020 Sep 2;30(5):765-782. doi: 10.1080/10543406.2020.1730873. Epub 2020 Feb 25.

DOI:10.1080/10543406.2020.1730873
PMID:32097079
Abstract

General Pairwise Comparison (GPC) statistics, such as the net benefit and the win ratio, have been applied in clinical trial data analysis and design. In the literature, inferential methods based on re-sampling, asymptotic or exact methods have been proposed for these GPC statistics, but they have not been compared to each other. In this paper, the small sample bias of the variance estimation, Type I error control and 95% confidence interval coverage of the GPC inferential methods are evaluated using simulations. The exact permutation and bootstrap tests perform best in all evaluated aspects for the net benefit, while the exact bootstrap test performs best for the win ratio.

摘要

一般成对比较(GPC)统计量,如净效益和胜率,已被应用于临床试验数据分析和设计。在文献中,已经提出了基于重抽样、渐近或精确方法的这些 GPC 统计量的推断方法,但尚未对它们进行相互比较。在本文中,使用模拟评估了 GPC 推断方法的方差估计的小样本偏差、I 类错误控制和 95%置信区间覆盖率。对于净效益,精确置换和引导检验在所有评估方面表现最好,而对于胜率,精确引导检验表现最好。

相似文献

1
Evaluation of inferential methods for the net benefit and win ratio statistics.净效益和胜率统计推断方法的评估。
J Biopharm Stat. 2020 Sep 2;30(5):765-782. doi: 10.1080/10543406.2020.1730873. Epub 2020 Feb 25.
2
The win odds: statistical inference and regression.获胜几率:统计推断与回归
J Biopharm Stat. 2023 Mar;33(2):140-150. doi: 10.1080/10543406.2022.2089156. Epub 2022 Aug 10.
3
On approximate equality of Z-values of the statistical tests for win statistics (win ratio, win odds, and net benefit).关于胜率统计(胜率、赢率和净收益)统计检验的Z值近似相等性。
J Biopharm Stat. 2025 May;35(3):457-464. doi: 10.1080/10543406.2024.2374857. Epub 2024 Oct 8.
4
Adjusting win statistics for dependent censoring.调整依赖删失的赢率统计。
Pharm Stat. 2021 May;20(3):440-450. doi: 10.1002/pst.2086. Epub 2020 Nov 28.
5
The use of the win odds in the design of non-inferiority clinical trials.在非劣效临床试验设计中使用赢率。
J Biopharm Stat. 2020 Sep 2;30(5):941-946. doi: 10.1080/10543406.2020.1757690. Epub 2020 May 31.
6
Robust statistical inference for matched win statistics.稳健的配对胜率统计推断。
Stat Methods Med Res. 2022 Aug;31(8):1423-1438. doi: 10.1177/09622802221090761. Epub 2022 May 16.
7
The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.胜率:删失和随访时间的影响以及与非比例风险的使用。
Pharm Stat. 2020 May;19(3):168-177. doi: 10.1002/pst.1977. Epub 2019 Oct 31.
8
A win ratio approach to comparing continuous non-normal outcomes in clinical trials.一种用于比较临床试验中连续非正态结果的胜率方法。
Pharm Stat. 2016 May;15(3):238-45. doi: 10.1002/pst.1743. Epub 2016 Mar 11.
9
Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method.使用合并重采样方法的非参数自助检验对小样本量研究进行分析。
Stat Med. 2017 Jun 30;36(14):2187-2205. doi: 10.1002/sim.7263. Epub 2017 Mar 9.
10
The asymptotic distribution of the Net Benefit estimator in presence of right-censoring.存在右删失时净效益估计量的渐近分布。
Stat Methods Med Res. 2021 Nov;30(11):2399-2412. doi: 10.1177/09622802211037067. Epub 2021 Oct 11.

引用本文的文献

1
Win Statistics in Observational Cancer Research: Integrating Clinical and Quality-of-Life Outcomes.观察性癌症研究中的获胜统计:整合临床和生活质量结果
J Clin Med. 2024 May 31;13(11):3272. doi: 10.3390/jcm13113272.
2
Istore: a project on innovative statistical methodologies to improve rare diseases clinical trials in limited populations.Istore:一个关于创新统计方法的项目,旨在改善有限人群中的罕见病临床试验。
Orphanet J Rare Dis. 2024 Mar 2;19(1):96. doi: 10.1186/s13023-024-03103-2.
3
Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial.
哌拉西林-他唑巴坦与美罗培南治疗头孢曲松不敏感的大肠埃希菌或肺炎克雷伯菌血流感染的疗效比较的优势比分析:来自 MERINO 试验的事后洞察。
Clin Infect Dis. 2024 Jun 14;78(6):1482-1489. doi: 10.1093/cid/ciae050.
4
Composite endpoints, including patient reported outcomes, in rare diseases.包含患者报告结局在内的复合终点指标在罕见病中的应用。
Orphanet J Rare Dis. 2023 Sep 1;18(1):262. doi: 10.1186/s13023-023-02819-x.
5
The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.逆概率删失加权(IPCW)调整后的赢率统计量:在独立删失存在下的无偏估计量。
J Biopharm Stat. 2020 Sep 2;30(5):882-899. doi: 10.1080/10543406.2020.1757692. Epub 2020 Jun 17.